{
    "analytics_identifier":  null,
    "base_path":  "/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
    "content_id":  "5a2038ab-aea3-464c-a0a9-c65f9c2aaeda",
    "description":  "Information on comparator products used in studies supporting abridged marketing authorisation application.",
    "details":  {
                    "attachments":  [

                                    ],
                    "body":  "\u003cdiv class=\"govspeak\"\u003e\u003ch2 id=\"overview\"\u003e1. Overview  \u003c/h2\u003e\n\n\u003ch3 id=\"until-and-including-31-december-2024\"\u003eUntil and including 31 December 2024 \u003c/h3\u003e\n\n\u003cp\u003eThis guidance is limited to applications intended for the Great Britain (England, Wales and Scotland) market only. Comparator products should be sourced from the Great Britain market and references to UK in this guidance should be read as applying to an application for a Great Britain only marketing authorisation (MA).   \u003c/p\u003e\n\n\u003cp\u003eApplications intended for Northern Ireland (including UK-wide applications) must comply with \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e requirements for comparator products to be used in bioequivalence and therapeutic equivalence studies and must be sourced from the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e/\u003cabbr title=\"European Economic Area\"\u003eEEA\u003c/abbr\u003e market.\u003c/p\u003e\n\n\u003ch3 id=\"from-1-january-2025\"\u003eFrom 1 January 2025 \u003c/h3\u003e\n\n\u003cp\u003eFollowing the implementation of new arrangements for human medicines as part of the Windsor Framework, this guidance will be applicable to UK-wide applications submitted on or after 1 January 2025.   \u003c/p\u003e\n\n\u003cp\u003eApplications for Northern Ireland-only marketing authorisations will need to continue to comply with \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e guidelines as they will be submitted through \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e mutual recognition or decentralised procedures.\u003c/p\u003e\n\n\u003ch3 id=\"reference-medicinal-products\"\u003e1.1 Reference medicinal products \u003c/h3\u003e\n\n\u003cp\u003eReference medicinal products (\u003cabbr title=\"reference medicinal products\"\u003eRMPs\u003c/abbr\u003e) for new generic medicines or other abridged marketing authorisation applications must comply with the requirements in Regulation 48(2) of the \u003ca rel=\"external\" href=\"https://www.legislation.gov.uk/uksi/2012/1916/contents\" class=\"govuk-link\"\u003eHuman Medicines Regulation 2012\u003c/a\u003e (the \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e) (as amended). \u003c/p\u003e\n\n\u003cp\u003eSee further \u003ca href=\"https://www.gov.uk/guidance/reference-medicinal-products-rmps\" class=\"govuk-link\"\u003eguidance on reference medicinal products\u003c/a\u003e.\u003c/p\u003e\n\n\u003ch3 id=\"comparator-products-used-in-bioequivalence-and-therapeutic-equivalence-studies\"\u003e1.2 Comparator products used in bioequivalence and therapeutic equivalence studies \u003c/h3\u003e\n\n\u003cp\u003eComparator products (\u003cabbr title=\"comparator products\"\u003eCPs\u003c/abbr\u003e) used in bioequivalence (\u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e), pharmacokinetic (\u003cabbr title=\"pharmacokinetic\"\u003ePK\u003c/abbr\u003e) and therapeutic equivalence (\u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e) studies supporting abridged applications should be representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e supporting the application. \u003c/p\u003e\n\n\u003cp\u003eGenerally, the \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e should be sourced from the UK. However, if the \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is not sourced from the UK market, the applicant should provide evidence that it is representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e. This guidance document provides further information on the data required to demonstrate this. \u003c/p\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e-published \u003ca rel=\"external\" href=\"https://assets.publishing.service.gov.uk/media/653108700b5392000da9299e/Bioequivalance_Biowaiver_Checklist_Abstract.docx\" class=\"govuk-link\"\u003echecklist for bioequivalence studies\u003c/a\u003e is helpful in considering study design. \u003c/p\u003e\n\n\u003ch2 id=\"scope\"\u003e2. Scope \u003c/h2\u003e\n\n\u003cp\u003eWith the aim of facilitating the global development of medicinal products and to avoid unnecessary repetition of clinical  \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies, it may be possible for an applicant to compare the proposed medicinal product with a non-UK sourced \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e. The application for the new medicinal product would still be required to refer to an eligible UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eThe purpose of demonstrating pharmaceutical equivalence and/or \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e against the \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is to provide evidence that the safety and efficacy profiles of the proposed product will be equivalent to that of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e for which safety and efficacy has been demonstrated. \u003c/p\u003e\n\n\u003cp\u003eIn order to determine the acceptability of this evidence, the licensing authority must be satisfied that a non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and that any differences between the two products would not be therapeutically significant. \u003c/p\u003e\n\n\u003cp\u003eThe following types of abridged applications are commonly supported by \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e or \u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies and are within the scope of this guidance: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003eapplications relating to generic medicinal products (regulation 51B\u003csup\u003e1\u003c/sup\u003e \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)  \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eapplications relating to hybrid medicinal products (that do not qualify as generics; submitted under regulation 52B\u003csup\u003e2\u003c/sup\u003e \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e) \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eapplications relating to new combinations of active substances (regulation 55(iii)(b) \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)  \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003evariations requiring demonstration of \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e to the \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e (for example, for modified release solid oral dosage forms) (regulation 65C \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)  \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eextension applications (regulation 65C \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)  \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003eAlso applies to Regulation 51A until 1 January 2025.\n\u003csup\u003e2\u003c/sup\u003eAlso applies to Regulation 52A until 1 January 2025.\u003c/p\u003e\n\n\u003cp\u003eThe principles may also be applicable to \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e, pharmacokinetic or \u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies conducted in support of other applications that are out of the scope of this guidance or certain non-clinical studies, for example those provided in support of hybrid applications (regulation 52B \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e). \u003c/p\u003e\n\n\u003cp\u003eNote that for applications for similar biological medical products (regulation 53 \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e) applicants should refer to \u003ca href=\"https://www.gov.uk/government/publications/guidance-on-the-licensing-of-biosimilar-products/guidance-on-the-licensing-of-biosimilar-products\" class=\"govuk-link\"\u003especific guidance on the licensing of biosimilar products\u003c/a\u003e.   \u003c/p\u003e\n\n\u003cp\u003eIf the use of a non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is proposed for applications that are out of the scope of this guidance, we recommend early discussion with the \u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e to obtain the relevant regulatory and/or scientific advice. \u003c/p\u003e\n\n\u003cp\u003eYou should always read this guidance in conjunction with relevant scientific guidelines and legislative provisions in force in the UK. \u003c/p\u003e\n\n\u003ch2 id=\"general-principles\"\u003e3. General principles \u003c/h2\u003e\n\n\u003cp\u003eThe general principles that are applicable are described below. For more specific guidance, especially for more complex dosage forms, we recommended that you seek scientific advice from the \u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e. \u003c/p\u003e\n\n\u003ch3 id=\"responsibility\"\u003e3.1 Responsibility \u003c/h3\u003e\n\n\u003cp\u003eIt is the applicant’s responsibility to demonstrate that any \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e authorised and sourced from outside the UK is representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e. \u003c/p\u003e\n\n\u003ch3 id=\"source-country-of-non-ukcp\"\u003e3.2 Source country of non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e \u003c/h3\u003e\n\n\u003cp\u003eThe non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e should be authorised by and sourced from a country with similar scientific and regulatory standards as the UK. Examples would be: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003e\u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e/\u003cabbr title=\"European Economic Area\"\u003eEEA\u003c/abbr\u003e \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eSwitzerland \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eUSA \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eCanada \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eAustralia \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eJapan \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eSingapore \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e would be expected to be: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003epart of the same global marketing authorisation (\u003cabbr title=\"Global Marketing Authorisation\"\u003eGMA\u003c/abbr\u003e) as the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e, or \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003emarketed in the country of origin through a licensing arrangement with the innovator company or corporate entity that currently markets the medicine in the UK\u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Global Marketing Authorisation\"\u003eGMA\u003c/abbr\u003e incorporates the initial authorisation and all variations and extensions. It includes any additional strengths, pharmaceutical forms, administration routes or presentations authorised through separate procedures and under different names, granted to the marketing authorisation holder (\u003cabbr title=\"marketing authorisation holder\"\u003eMAH\u003c/abbr\u003e) of the initial authorisation. \u003c/p\u003e\n\n\u003ch3 id=\"identicality-vs-representativeness\"\u003e3.3 Identicality vs. representativeness \u003c/h3\u003e\n\n\u003cp\u003eThe non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e used must be representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e, but it does not need to be identical to it. This means that certain minor differences between both products may be accepted provided this is supported by bridging data (see below) or otherwise justified. \u003c/p\u003e\n\n\u003cp\u003eThese differences could include but are not limited to: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003ecolour of tablet coatings (assuming no difference in functionality of coat) or capsule shells \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003escorelines, embossing and imprinting on solid dosage forms \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eflavours in liquid dosage forms \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003econtainer closures \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch3 id=\"demonstration-of-identicality-of-the-non-ukcpto-theuk-rmp\"\u003e3.4 Demonstration of identicality of the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e to the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e \u003c/h3\u003e\n\n\u003cp\u003eIn cases where the applicant provides written confirmation from the \u003cabbr title=\"marketing authorisation holder\"\u003eMAH\u003c/abbr\u003e of the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e that the \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is identical to the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e, no further analytical data are required. \u003c/p\u003e\n\n\u003cp\u003eThis written confirmation should confirm the following are identical in both products: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003ethe drug substance specifications \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ethe finished product quantitative composition \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ethe finished product manufacturing process including in-process controls \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ethe finished product specifications \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ethe stability data \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIn cases where identicality can be confirmed, the use of a non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is also acceptable for more complex formulations. \u003c/p\u003e\n\n\u003cp\u003eFor the drug substance and finished product specifications, non-significant differences in specifications may be acceptable, if fully justified. \u003c/p\u003e\n\n\u003ch3 id=\"demonstration-of-representativeness-of-the-non-ukcpto-theukrmp\"\u003e3.5 Demonstration of representativeness of the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e to the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e \u003c/h3\u003e\n\n\u003cp\u003eIf a \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e authorised and sourced from outside UK is used, there is no letter of confirmation from the \u003cabbr title=\"marketing authorisation holder\"\u003eMAH\u003c/abbr\u003e of the \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e stating it is identical to the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e, or if the product does not fall within the scenarios in section 3.6, the applicant should provide adequate data or information to establish an acceptable bridge to the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e. The relevance of these comparative data should be scientifically justified. \u003c/p\u003e\n\n\u003cp\u003eAs a scientific matter, the type of bridging data needed should always include data from analytical studies as indicated below: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003ebetween the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e to establish suitability of the latter as \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e in \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ebetween the proposed medicinal product and the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e to support the \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eAny observed differences in the data must be justified with regard to their potential impact on the safety and efficacy of the proposed product. \u003c/p\u003e\n\n\u003cp\u003eOnly data requirements between the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e are discussed here; for other data requirements please \u003ca rel=\"external\" href=\"https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf\" class=\"govuk-link\"\u003esee current guidelines on the investigation of bioequivalence\u003c/a\u003e. \u003c/p\u003e\n\n\u003cp\u003eThe following information for both the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e should be provided in Module 1.5.2 of the common technical document: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003ename and address of the authorisation holder of the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e used, the product name, the country of authorisation, country of source and authorisation number\u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eproof of purchase (batch number, date and place of purchase, expiry date)\u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003econfirmation that samples in their original container closure systems are available upon request\u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eproduct information (summary of product characteristics or equivalent)\u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ecertificates of analysis (tested according to the proposed specification for the proposed medicinal product) \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ea comparison of the excipients in the formulation of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e, when compared to the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e (the excipients should be qualitatively the same; any differences in excipients would need to be shown, or otherwise justified, as having no effect on safety or efficacy \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eif available, a comparison of the quantitative formulations of the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e and the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e (if this information is available, it should show the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e to be representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e) \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe experimental comparison should include the physico-chemical properties and all critical quality attributes of the medicinal product. These should include device attributes where appropriate. Where provided, dissolution data should cover the physiological pH range and take account of current guidance on the development and choice of test conditions. The method used should have been shown to be discriminatory. \u003c/p\u003e\n\n\u003ch3 id=\"number-of-batches-to-be-tested\"\u003e3.6 Number of batches to be tested \u003c/h3\u003e\n\n\u003cp\u003eThe number of batches needed to demonstrate that the non-UK comparator product is representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e should be justified on the basis of the complexity of the dosage form and method of manufacture.   \u003c/p\u003e\n\n\u003cp\u003eTo provide assurance of representativeness between the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e, we would usually expect data on at least 3 batches of each product.   \u003c/p\u003e\n\n\u003cp\u003eIn cases where the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e have a recent shared regulatory history,   applicants may be able to justify representativeness without further batch testing.   \u003c/p\u003e\n\n\u003cp\u003eThis utilises the principle that post-authorisation changes to products that have more than a minor impact on quality have been reviewed by the relevant regulatory authorities to ensure that they do not impact on the safety, efficacy or overall balance of benefit and risk. \u003c/p\u003e\n\n\u003cp\u003eJustification based on shared regulatory history will be considered where the comparator product is: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003ea centrally authorised product that has, until 31 December 2024, been authorised for Northern Ireland \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ea product authorised through MRP/DCP (mutual recognition procedure decentralised procedures) where Northern Ireland is or was a concerned member state (CMS)  \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThis will not normally be acceptable for products that fall into any of the categories described in section 3.8.  \u003c/p\u003e\n\n\u003cp\u003eIn cases of products that exhibit a higher inherent batch-to-batch variability or that are complex, further evidence from a larger number of batches may be required to establish representativeness. \u003c/p\u003e\n\n\u003ch3 id=\"analytical-methods\"\u003e3.7 Analytical methods \u003c/h3\u003e\n\n\u003cp\u003eThe validity of the analytical methods and the inter-batch variability are critical to deciding if the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e is representative of the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e. The analytical methods and analytical method validation reports used to generate the comparative data should be provided. \u003c/p\u003e\n\n\u003cp\u003eTest methods should be shown to be robust in line with current \u003ca rel=\"external\" href=\"https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf\" class=\"govuk-link\"\u003eguidance on method development and validation\u003c/a\u003e.   \u003c/p\u003e\n\n\u003cp\u003eDissolution tests for oral solid dosage forms should be shown to be discriminatory as set out in \u003ca rel=\"external\" href=\"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-dissolution-specification-generic-solid-oral-immediate-release-products-systemic-action-first-version_en.pdf\" class=\"govuk-link\"\u003eReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action (europa.eu)\u003c/a\u003e.   \u003c/p\u003e\n\n\u003ch3 id=\"acceptability-of-approach\"\u003e3.8 Acceptability of approach \u003c/h3\u003e\n\n\u003cp\u003eIn cases without confirmation from the \u003cabbr title=\"marketing authorisation holder\"\u003eMAH\u003c/abbr\u003e that the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e and the non-UK comparator product are identical, the overall acceptability of the approach to justify or demonstrate representativeness will be a case-by-case/product-type decision. We recommend that you discuss it with the \u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e before submission if one or more of the following applies.  \u003c/p\u003e\n\n\u003cp\u003eThe product: \u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n    \u003cp\u003edoes not exhibit immediate release of the drug substance \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eis not for oral administration \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eis for parenteral administration but is not a simple solution \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003einvolves complex methods of manufacture \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eexhibits a narrow therapeutic range or safety margin (for example, careful dosage titration or patient monitoring is required) \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ehas a steep dose-response relationship \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ehas a risk of serious undesired effects \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003eexhibits complicated or variable pharmacokinetics (such as nonlinear pharmacokinetics, variable or incomplete absorption) \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ehas a physiological absorption window (that is, site-specific absorption) \u003c/p\u003e\n  \u003c/li\u003e\n  \u003cli\u003e\n    \u003cp\u003ehas substantial (for example, greater than 40%) first-pass metabolism \u003c/p\u003e\n  \u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe final determination of the adequacy of the scientific justification and bridging will only be made during the assessment of the application. This will take the quality, safety and efficacy of the medicinal product into account. \u003c/p\u003e\n\n\u003cp\u003eIf representativeness between the non-UK \u003cabbr title=\"comparator product\"\u003eCP\u003c/abbr\u003e and the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e cannot be demonstrated, \u003cabbr title=\"bioequivalence\"\u003eBE\u003c/abbr\u003e or \u003cabbr title=\"therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies should be performed against the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e. Where this is not possible, for example because the UK \u003cabbr title=\"reference medicinal product\"\u003eRMP\u003c/abbr\u003e is no longer available, an alternative legal basis of submission, for example, Regulations 54 (well-established use) or 50 (full, mixed dossier) of the \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e will need to be considered.  \u003c/p\u003e\n\n\u003ch2 id=\"contact\"\u003e4. Contact \u003c/h2\u003e\n\n\u003cp\u003eFor further information, email \u003ca href=\"mailto:RIS.NA@mhra.gov.uk\" class=\"govuk-link\"\u003eRIS.NA@mhra.gov.uk\u003c/a\u003e.\u003c/p\u003e\n\n\u003c/div\u003e",
                    "change_history":  [
                                           {
                                               "note":  "Added section numbers and document overview.  \r\nUpdated all sections for clarity and territorial changes – GB revised to UK. \r\nUpdated references to applicable regulations.\r\nUpdated section 3.2 list of acceptable regulator countries. \r\n\r\nUpdated section 4 contact details ",
                                               "public_timestamp":  "2024-12-20T12:47:48.000+00:00"
                                           },
                                           {
                                               "note":  "First published.",
                                               "public_timestamp":  "2020-12-31T00:00:00.000+00:00"
                                           }
                                       ],
                    "emphasised_organisations":  [
                                                     "240f72bd-9a4d-4f39-94d9-77235cadde8e"
                                                 ],
                    "first_public_at":  "2020-12-31T00:00:00.000+00:00",
                    "political":  false,
                    "related_mainstream_content":  [

                                                   ],
                    "tags":  {
                                 "browse_pages":  [

                                                  ]
                             }
                },
    "document_type":  "detailed_guide",
    "first_published_at":  "2020-12-31T00:00:00+00:00",
    "links":  {
                  "available_translations":  [
                                                 {
                                                     "api_path":  "/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                     "api_url":  "https://www.gov.uk/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                     "base_path":  "/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                     "content_id":  "5a2038ab-aea3-464c-a0a9-c65f9c2aaeda",
                                                     "document_type":  "detailed_guide",
                                                     "links":  {

                                                               },
                                                     "locale":  "en",
                                                     "public_updated_at":  "2024-12-20T12:47:48Z",
                                                     "schema_name":  "detailed_guide",
                                                     "title":  "Comparator products in bioequivalence/therapeutic equivalence studies",
                                                     "web_url":  "https://www.gov.uk/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                     "withdrawn":  false
                                                 }
                                             ],
                  "document_collections":  [
                                               {
                                                   "api_path":  "/api/content/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "base_path":  "/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "content_id":  "aecc31f9-1d53-4c18-9df4-4e5940323c4f",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "base_path":  "/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "content_id":  "5a2038ab-aea3-464c-a0a9-c65f9c2aaeda",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2024-12-20T12:47:48Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Comparator products in bioequivalence/therapeutic equivalence studies",
                                                                                       "web_url":  "https://www.gov.uk/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2021-03-30T10:06:39Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "New guidance and information for industry from the MHRA",
                                                   "web_url":  "https://www.gov.uk/government/collections/new-guidance-and-information-for-industry-from-the-mhra",
                                                   "withdrawn":  false
                                               },
                                               {
                                                   "api_path":  "/api/content/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "api_url":  "https://www.gov.uk/api/content/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "base_path":  "/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "content_id":  "a3deaf0f-3161-40a1-b122-02d016fcb526",
                                                   "document_type":  "document_collection",
                                                   "links":  {
                                                                 "documents":  [
                                                                                   {
                                                                                       "api_path":  "/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "api_url":  "https://www.gov.uk/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "base_path":  "/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "content_id":  "5a2038ab-aea3-464c-a0a9-c65f9c2aaeda",
                                                                                       "document_type":  "detailed_guide",
                                                                                       "links":  {

                                                                                                 },
                                                                                       "locale":  "en",
                                                                                       "public_updated_at":  "2024-12-20T12:47:48Z",
                                                                                       "schema_name":  "detailed_guide",
                                                                                       "title":  "Comparator products in bioequivalence/therapeutic equivalence studies",
                                                                                       "web_url":  "https://www.gov.uk/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies",
                                                                                       "withdrawn":  false
                                                                                   }
                                                                               ]
                                                             },
                                                   "locale":  "en",
                                                   "public_updated_at":  "2021-01-07T00:00:00Z",
                                                   "schema_name":  "document_collection",
                                                   "title":  "Moving goods into, out of, or through Northern Ireland",
                                                   "web_url":  "https://www.gov.uk/government/collections/moving-goods-into-out-of-or-through-northern-ireland",
                                                   "withdrawn":  false
                                               }
                                           ],
                  "government":  [
                                     {
                                         "api_path":  "/api/content/government/2019-to-2022-johnson-conservative-government",
                                         "api_url":  "https://www.gov.uk/api/content/government/2019-to-2022-johnson-conservative-government",
                                         "base_path":  "/government/2019-to-2022-johnson-conservative-government",
                                         "content_id":  "4ed901ec-c8ce-42d5-a2aa-6d7f462480df",
                                         "details":  {
                                                         "current":  false,
                                                         "ended_on":  "2022-09-06T00:00:00+00:00",
                                                         "started_on":  "2019-07-24T00:00:00+00:00"
                                                     },
                                         "document_type":  "government",
                                         "links":  {

                                                   },
                                         "locale":  "en",
                                         "title":  "2019 to 2022 Johnson Conservative government",
                                         "web_url":  "https://www.gov.uk/government/2019-to-2022-johnson-conservative-government"
                                     }
                                 ],
                  "organisations":  [
                                        {
                                            "analytics_identifier":  "EA63",
                                            "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                            "details":  {
                                                            "acronym":  "MHRA",
                                                            "brand":  "department-of-health",
                                                            "default_news_image":  null,
                                                            "logo":  {
                                                                         "crest":  "single-identity",
                                                                         "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                     },
                                                            "organisation_govuk_status":  {
                                                                                              "status":  "live",
                                                                                              "updated_at":  null,
                                                                                              "url":  null
                                                                                          }
                                                        },
                                            "document_type":  "organisation",
                                            "links":  {

                                                      },
                                            "locale":  "en",
                                            "schema_name":  "organisation",
                                            "title":  "Medicines and Healthcare products Regulatory Agency",
                                            "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "withdrawn":  false
                                        }
                                    ],
                  "original_primary_publishing_organisation":  [
                                                                   {
                                                                       "analytics_identifier":  "EA63",
                                                                       "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                                       "details":  {
                                                                                       "acronym":  "MHRA",
                                                                                       "brand":  "department-of-health",
                                                                                       "default_news_image":  null,
                                                                                       "logo":  {
                                                                                                    "crest":  "single-identity",
                                                                                                    "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                                },
                                                                                       "organisation_govuk_status":  {
                                                                                                                         "status":  "live",
                                                                                                                         "updated_at":  null,
                                                                                                                         "url":  null
                                                                                                                     }
                                                                                   },
                                                                       "document_type":  "organisation",
                                                                       "links":  {

                                                                                 },
                                                                       "locale":  "en",
                                                                       "schema_name":  "organisation",
                                                                       "title":  "Medicines and Healthcare products Regulatory Agency",
                                                                       "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "withdrawn":  false
                                                                   }
                                                               ],
                  "primary_publishing_organisation":  [
                                                          {
                                                              "analytics_identifier":  "EA63",
                                                              "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                              "details":  {
                                                                              "acronym":  "MHRA",
                                                                              "brand":  "department-of-health",
                                                                              "default_news_image":  null,
                                                                              "logo":  {
                                                                                           "crest":  "single-identity",
                                                                                           "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                       },
                                                                              "organisation_govuk_status":  {
                                                                                                                "status":  "live",
                                                                                                                "updated_at":  null,
                                                                                                                "url":  null
                                                                                                            }
                                                                          },
                                                              "document_type":  "organisation",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "schema_name":  "organisation",
                                                              "title":  "Medicines and Healthcare products Regulatory Agency",
                                                              "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "suggested_ordered_related_items":  [
                                                          {
                                                              "api_path":  "/api/content/guidance/types-of-application-legal-basis",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/types-of-application-legal-basis",
                                                              "base_path":  "/guidance/types-of-application-legal-basis",
                                                              "content_id":  "81dd8ca0-9397-4443-9d0c-4c63115d12f0",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2021-03-31T13:11:42Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Types of application (legal basis)",
                                                              "web_url":  "https://www.gov.uk/guidance/types-of-application-legal-basis",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/marketing-authorisation-application-submission-dates-for-150-days-national-and-european-commission-decision-reliance-procedures",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/marketing-authorisation-application-submission-dates-for-150-days-national-and-european-commission-decision-reliance-procedures",
                                                              "base_path":  "/guidance/marketing-authorisation-application-submission-dates-for-150-days-national-and-european-commission-decision-reliance-procedures",
                                                              "content_id":  "f493c6b2-2bb6-46a8-b51a-014c33751c40",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2023-09-12T09:15:44Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Marketing Authorisation Application submission dates for 150-days national and European Commission decision reliance procedures",
                                                              "web_url":  "https://www.gov.uk/guidance/marketing-authorisation-application-submission-dates-for-150-days-national-and-european-commission-decision-reliance-procedures",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/reference-medicinal-products-rmps",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/reference-medicinal-products-rmps",
                                                              "base_path":  "/guidance/reference-medicinal-products-rmps",
                                                              "content_id":  "d64bf3fc-32f7-4eea-a298-b6a59683a674",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-10-18T15:51:46Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Reference Medicinal Products (RMPs)",
                                                              "web_url":  "https://www.gov.uk/guidance/reference-medicinal-products-rmps",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/supplying-investigational-medicinal-products-to-northern-ireland",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/supplying-investigational-medicinal-products-to-northern-ireland",
                                                              "base_path":  "/guidance/supplying-investigational-medicinal-products-to-northern-ireland",
                                                              "content_id":  "ff3a941a-e775-4e13-aee7-ab8c34b9aeb2",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2021-12-22T15:25:31Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Supplying investigational medicinal products to Northern Ireland",
                                                              "web_url":  "https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland",
                                                              "withdrawn":  false
                                                          },
                                                          {
                                                              "api_path":  "/api/content/guidance/guidance-on-new-provisions-for-traditional-herbal-medicinal-products-and-homoeopathic-medicinal-products",
                                                              "api_url":  "https://www.gov.uk/api/content/guidance/guidance-on-new-provisions-for-traditional-herbal-medicinal-products-and-homoeopathic-medicinal-products",
                                                              "base_path":  "/guidance/guidance-on-new-provisions-for-traditional-herbal-medicinal-products-and-homoeopathic-medicinal-products",
                                                              "content_id":  "25b65ec1-251d-41c3-8316-0bfda0f4c6f2",
                                                              "document_type":  "detailed_guide",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2024-12-31T16:52:03Z",
                                                              "schema_name":  "detailed_guide",
                                                              "title":  "Guidance on new provisions for traditional herbal medicinal products and homeopathic medicinal products",
                                                              "web_url":  "https://www.gov.uk/guidance/guidance-on-new-provisions-for-traditional-herbal-medicinal-products-and-homoeopathic-medicinal-products",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "taxons":  [
                                 {
                                     "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "base_path":  "/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "content_id":  "f4f28e9d-2050-45fb-ab76-78c0345670da",
                                     "details":  {
                                                     "internal_name":  "Marketing authorisations, variations and licensing guidance [T]",
                                                     "notes_for_editors":  "",
                                                     "visible_to_departmental_editors":  false
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "base_path":  "/health-and-social-care/medicines-medical-devices-blood",
                                                                             "content_id":  "cebc01ee-f70a-4397-a552-622e10b62508",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Medicines and medical devices [T] (level 2, health theme)",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  false
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "parent_taxons":  [
                                                                                                                 {
                                                                                                                     "api_path":  "/api/content/health-and-social-care",
                                                                                                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care",
                                                                                                                     "base_path":  "/health-and-social-care",
                                                                                                                     "content_id":  "8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8",
                                                                                                                     "description":  "",
                                                                                                                     "details":  {
                                                                                                                                     "internal_name":  "Health and social care",
                                                                                                                                     "notes_for_editors":  "",
                                                                                                                                     "visible_to_departmental_editors":  true
                                                                                                                                 },
                                                                                                                     "document_type":  "taxon",
                                                                                                                     "links":  {
                                                                                                                                   "root_taxon":  ""
                                                                                                                               },
                                                                                                                     "locale":  "en",
                                                                                                                     "phase":  "live",
                                                                                                                     "public_updated_at":  "2018-09-16T20:30:51Z",
                                                                                                                     "schema_name":  "taxon",
                                                                                                                     "title":  "Health and social care",
                                                                                                                     "web_url":  "https://www.gov.uk/health-and-social-care",
                                                                                                                     "withdrawn":  false
                                                                                                                 }
                                                                                                             ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2019-02-06T16:16:55Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Medicines, medical devices",
                                                                             "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2018-08-22T12:56:21Z",
                                     "schema_name":  "taxon",
                                     "title":  "Marketing authorisations, variations and licensing guidance",
                                     "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "withdrawn":  false
                                 },
                                 {
                                     "api_path":  "/api/content/government/brexit",
                                     "api_url":  "https://www.gov.uk/api/content/government/brexit",
                                     "base_path":  "/government/brexit",
                                     "content_id":  "d6c2de5d-ef90-45d1-82d4-5f2438369eea",
                                     "description":  "Find out how new Brexit rules apply to things like travel and doing business with Europe.",
                                     "details":  {
                                                     "internal_name":  "Brexit",
                                                     "notes_for_editors":  "",
                                                     "url_override":  "/government/collections/brexit-guidance",
                                                     "visible_to_departmental_editors":  true
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/government/all",
                                                                             "api_url":  "https://www.gov.uk/api/content/government/all",
                                                                             "base_path":  "/government/all",
                                                                             "content_id":  "e48ab80a-de80-4e83-bf59-26316856a5f9",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Government",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  true
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "root_taxon":  [
                                                                                                              {
                                                                                                                  "api_path":  "/api/content/",
                                                                                                                  "api_url":  "https://www.gov.uk/api/content/",
                                                                                                                  "base_path":  "/",
                                                                                                                  "content_id":  "f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a",
                                                                                                                  "document_type":  "homepage",
                                                                                                                  "links":  {

                                                                                                                            },
                                                                                                                  "locale":  "en",
                                                                                                                  "public_updated_at":  "2023-06-28T09:32:34Z",
                                                                                                                  "schema_name":  "homepage",
                                                                                                                  "title":  "GOV.UK homepage",
                                                                                                                  "web_url":  "https://www.gov.uk/",
                                                                                                                  "withdrawn":  false
                                                                                                              }
                                                                                                          ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2018-09-16T20:29:39Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Government",
                                                                             "web_url":  "https://www.gov.uk/government/all",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2024-11-14T17:47:34Z",
                                     "schema_name":  "taxon",
                                     "title":  "Brexit",
                                     "web_url":  "https://www.gov.uk/government/brexit",
                                     "withdrawn":  false
                                 }
                             ]
              },
    "locale":  "en",
    "phase":  "live",
    "public_updated_at":  "2024-12-20T12:47:48+00:00",
    "publishing_app":  "whitehall",
    "publishing_request_id":  "21-1734698868.564-10.13.22.155-2735",
    "publishing_scheduled_at":  "2020-12-31T23:00:00+00:00",
    "rendering_app":  "government-frontend",
    "scheduled_publishing_delay_seconds":  163,
    "schema_name":  "detailed_guide",
    "title":  "Comparator products in bioequivalence/therapeutic equivalence studies",
    "updated_at":  "2024-12-31T16:52:03+00:00",
    "withdrawn_notice":  {

                         }
}
